Rigel Pharmaceuticals
Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated to improving the lives of patients through the discovery, development, and commercialization of novel small molecule drugs. In particular, Rigel is focused on immune and hematologic disorders, cancer, and rare diseases. Rigel views great opportunity to help patients who have diseases where few to no approved treatment options exist.
Rigel’s first FDA approved product TAVALISSE® (fostamatinib disodium hexahydrate) tablets was approved in 2018. Please visit www.TAVALISSE.com to see the full Prescribing Information and to learn more.
Visit Rigel at booth #415 to learn more and support the ASH Foundation.